[
    {
        "score": 4.517182350158691,
        "text": "presentation owing to advanced underlying \nliver disease. Liver transplantation is an optimal \ntreatment option for early stage, unresectable \nhepatocellular carcinoma in patients with cirrhosis \nbecause it treats the underlying cirrhosis as well as \nhepatocellular carcinoma and is associated with a \nsignificantly reduced incidence of recurrent cancer \ncompared with alternative treatment strategies. Liver \ntransplantation for hepatocellular carcinoma within \nthe Milan criteria (one lesion between 3 and 5 cm, or \ntwo to three lesions between 1 and 3 cm) has been \nlong established as the standard criteria for patient \nselection.65 Based on the success of the Milan criteria, \nadditional proposals to allow access for patients \nwith larger tumors have been developed. The most \nwell known of these are the University of California, \nSan Francisco (UCSF) criteria (81% survival at five \nyears), up-to-seven criteria (71% survival at five \nyears), total tumor volume (75% survival at four \nyears), extended Toronto criteria (68% survival at \nfive years), and Kyoto criteria (65% survival at five \nyears).66-70 Each proposal expands the selection \ncriteria, allowing more patients to be considered for \nliver transplantation, while showing reduced but \nexcellent long term outcomes after transplantation.\nThe primary limitation of liver transplantation \nfor hepatocellular carcinoma is the critical shortage \nof available liver allografts, and thus the patient\u2019s \nsurvival without timely access to transplantation as \nwell as the expected survival after transplantation \nmust be considered, which is best estimated \nby disease burden. In the US, patients with \nhepatocellular carcinoma, with \u03b1 fetoprotein lower \nthan 1000 ng/mL, and who are either within Milan \ncriteria or downstaged to within Milan criteria from \nspecific downstaging criteria (up to five lesions, sum \nof lesion diameters <8 cm) are eligible to receive \nadditional waitlist priority after a six month waiting \nperiod.71 72 Since May 2019, patients receive a fixed \nscore 3 points lower than the median MELD (model \nfor end-stage liver disease) at transplant (MMaT-3) for \nthe area of distribution where they are listed, which \nis currently based on a concentric circle model.72\nThe primary goal of MMaT-3 is to assign a score \nthat is adjusted according to the score required \nto access transplantation in the area where the \npatient is listed, given the differences around the \nUS in access to transplantation. A secondary goal \nis to manage the observed and continued rise in the \nMELD score at transplantation over the past decade, \nwhich is thought to be potentially related to the \nprior system of stepwise increases in the exception \nMELD score granted every three months to patients \nwith hepatocellular carcinoma awaiting liver Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. \n. Technical Services Serials\nat New York University, Serials Bobst Library on 3 November 2025 https://www.bmj.com/ Downloaded from 26 October 2020. 10.1136/bmj.m3544 on BMJ: first published as",
        "chunk_id": 10,
        "paper_title": "New advances in the diagnosis and management of",
        "doi": "10_1136_bmj_m3544",
        "year": 2020.0,
        "filename": "10_1136_bmj_m3544.txt"
    },
    {
        "score": 4.457963466644287,
        "text": "transplantation criteria for patients with hepatocellular \ncarcinoma based on the Japanese nationwide survey: the \n5-5-500 rule - a retrospective study. Transpl Int. 2019; \n32:356-368.\n11. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific \nAssociation for the Study of the Liver consensus \nrecommendations on hepatocellular carcinoma. Hepatol \nInt. 2010; 4:439-474.\n12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter \nY, Alonso-Coello P, Sch\u00fcnemann HJ; GRADE Working \nGroup. GRADE: an emerging consensus on rating quality \nof evidence and strength of recommendations. BMJ. 2008; \n336:924-926.\n13. Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida \nH, Matsuda S, Koike K. Mortality and morbidity of \nhepatectomy, radiofrequency ablation, and embolization \nfor hepatocellular carcinoma: a national survey of 54,145 \npatients. J Gastroenterol. 2012; 47:1125-1133.\n14. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti \nL, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, \nDonadon M, Morenghi E, Makuuchi M. A snapshot \nof the effective indications and results of surgery for \nhepatocellular carcinoma in tertiary referral centers: is \nit adherent to the EASL/AASLD recommendations? An \nobservational study of the HCC East-West study group. \nAnn Surg. 2013; 257:929-937.\n15. Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular \ncarcinoma: the BCLC staging classification. Semin Liver \nDis. 1999; 19:329-338.\n16. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti \nA, Bozzetti F, Montalto F, Ammatuna M, Morabito A, \nGennari L. Liver transplantation for the treatment of small \nhepatocellular carcinomas in patients with cirrhosis. N \nEngl J Med. 1996; 334:693-699.\n17. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, \nIzumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, \nNakashima O, Kaneko S, Kokudo N; Liver Cancer Study \nGroup of Japan. Survival benefit of liver resection for \nhepatocellular carcinoma associated with portal vein \ninvasion. J Hepatol. 2016; 65:938-943.\n18. Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, \nLi H, Beer TM. Patient-physician disagreement regarding \nperformance status is associated with worse survivorship \nin patients with advanced cancer. Cancer. 2008; 113:2205-\n2214.\n19. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, \nPark JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian \nconsensus workshop report: expert consensus guideline \n(290)\nwww.globalhealthmedicine.com",
        "chunk_id": 12,
        "paper_title": "Difference in treatment algorithms for hepatocellular carcinoma",
        "doi": "10_35772_ghm_2020_01066",
        "year": 2005.0,
        "filename": "10_35772_ghm_2020_01066.txt"
    },
    {
        "score": 4.421480178833008,
        "text": "hepatocellular carcinoma to within milan criteria: a multicenter study, Clin. \nGastroenterol. Hepatol.: Off Clin. Prac. J. Am. Gastroenterol. Assoc. 16 (6) (2018) \n955\u2013964. \n[28] W.C. Chapman, S. Garcia-Aroz, N. Vachharajani, K. Fowler, N. Saad, Y. Lin, et al., \nLiver transplantation for advanced hepatocellular carcinoma after downstaging \nwithout up-front stage restrictions, J. Am. Coll. Surg. (2017). \n[29] G. Sapisochin, N. Goldaracena, J.M. Laurence, M. Dib, A. Barbas, A. Ghanekar, et \nal., The extended Toronto criteria for liver transplantation in patients with \nhepatocellular carcinoma: a prospective validation study, Hepatology 64 (6) \n(2016) 2077\u20132088. \nH. Degroote et al.",
        "chunk_id": 12,
        "paper_title": "Surgical Oncology 33 (2020) 231\u2013238",
        "doi": "10_1016_j_suronc_2019_10_006",
        "year": 2019.0,
        "filename": "10_1016_j_suronc_2019_10_006.txt"
    },
    {
        "score": 4.243038654327393,
        "text": "Suppl 3: S10\u201312.\n11. Loffroy R (2011) Interventional radiology for hepatocellular carcinoma. Minerva\nGastroenterol Dietol 57: 299\u2013309.\n12. Lubienski A (2005) Hepatocellular carcinoma: interventional bridging to liver\ntransplantation. Transplantation 80: S113\u2013119.\n13. Otto G, Herber S, Heise M, Lohse AW, Mo\u00a8nch C, et al. (2006) Response to\ntransarterial chemoembolization as a biological selection criterion for liver\ntransplantation in hepatocellular carcinoma. Liver Transpl 12: 1260\u20131267.\n14. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, et al.\n(2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage\nhepatocellular carcinoma before liver transplantation. Ann Surg 248: 617\u2013625.\n15. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, et al. (2008) Liver\ntransplantation for hepatocellular carcinoma: results of down-staging in patients\ninitially outside the Milan selection criteria. Am J Transplant 8: 2547\u20132557.\n16. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. (2012) OLT for\nHCC Consensus Group. Recommendations for liver transplantation for\nhepatocellular carcinoma: an international consensus conference report. Lancet\nOncol 13: e11\u201322.\n17. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, et al. (2011)\nEfficacy of selective transarterial chemoembolization in inducing tumor necrosis\nin small (,5 cm) hepatocellular carcinomas. Hepatology 53: 1580\u20131589.\n18. Kornberg A, Ku\u00a8pper B, Thrum K, Katenkamp K, Steenbeck J, et al. (2009)\nIncreased 18F-FDG uptake of hepatocellular carcinoma on positron emission\ntomography independently predicts tumor recurrence in liver transplant\npatients. Transplant Proc 41: 2561\u20132563.\n19. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, et al. (2009) Prediction of\ntumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular\ncarcinoma. J Nucl Med 50: 682\u2013687.\n20. Kornberg A, Ku\u00a8pper B, Thrum K, Wilberg J, Sappler A, et al. (2009)\nRecurrence-free long-term survival after liver transplantation in patients with\n18F-FDG non-avid hilar cholangiocarcinoma on PET. Am J Transplant 9:\n2631\u20132636.\n21. Gadaleta CD, Ranieri G (2011) Trans-arterial chemoembolization as a therapy\nfor liver tumours: New clinical developments and suggestions for combination\nwith angiogenesis inhibitors. Crit Rev Oncol Hematol 80: 40\u201353.\n22. Minami Y, Kudo M (2011) Review of dynamic contrast-enhanced ultrasound\nguidance in ablation therapy for hepatocellular carcinoma.\nWorld J Gastroenterol.;17: 4952\u20134959.\n23. Tiong L, Maddern GJ (2011) Systematic review and meta-analysis of survival\nand disease recurrence after radiofrequency ablation for hepatocellular\ncarcinoma. Br J Surg 98: 1210\u20131224.\n24. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, et al. (1997) Influence of\npreoperative transarterial lipiodol chemoembolization on resection and\ntransplantation for hepatocellular carcinoma in patients with cirrhosis. Ann\nSurg 226: 688\u2013701.\n25. Lesurtel M, Mu\u00a8llhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006)\nTransarterial chemoembolization as a bridge to liver transplantation for\nhepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:\n2644\u20132650.\n26. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, et al.\n(2005) Impact of pretransplantation transarterial chemoembolization on survival\nand recurrence after liver transplantation for hepatocellular carcinoma. Liver\nTranspl 11: 767\u2013775.\n27. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, et al. (2004)\nDrop-out rates of patients with hepatocellular cancer listed for liver\ntransplantation: outcome with chemoembolization. Liver Transpl 10: 449\u2013455.\n28. Schwartz ME, D\u2019Amico F, Vitale A, Emre S, Cillo U (2008) Liver\ntransplantation for hepatocellular carcinoma: Are the Milan criteria still valid?\nEur J Surg Oncol 34: 256\u2013262.\n29. Silva MF, Sherman M (2011) Criteria for liver transplantation for HCC: what\nshould the limits be? J Hepatol 55: 1137\u20131147.",
        "chunk_id": 13,
        "paper_title": "Extended Postinterventional Tumor Necrosis\u2014",
        "doi": "10_1371_journal_pone_0053960",
        "year": 2013.0,
        "filename": "10_1371_journal_pone_0053960.txt"
    },
    {
        "score": 4.046337604522705,
        "text": "129\u2013137. \n[13] C. Toso, S. Asthana, D.L. Bigam, A.M. Shapiro, N.M. Kneteman, Reassessing \nselection criteria prior to liver transplantation for hepatocellular carcinoma \nutilizing the Scientific Registry of Transplant Recipients database, Hepatology 49 \n(3) (2009) 832\u2013838. \n[14] Q. Lai, D. Nicolini, M. Inostroza Nunez, S. Iesari, P. Goffette, A. Agostini, et al., \nA novel prognostic index in patients with hepatocellular cancer waiting for liver \ntransplantation: time-radiological-response-alpha-fetoprotein-inflammation \n(TRAIN) score, Ann. Surg. (2016). \n[15] Q. Lai, A. Vitale, S. Iesari, A. Finkenstedt, G. Mennini, G. Spoletini, et al., Intention\ufffeto-treat survival benefit of liver transplantation in patients with hepatocellular \ncancer, Hepatology 66 (6) (2017) 1910\u20131919. \n[16] K.J. Halazun, P. Tabrizian, M. Najjar, S. Florman, M. Schwartz, F. Michelassi, et al., \nIs it time to abandon the milan criteria?: results of a bicoastal US collaboration to \nredefine hepatocellular carcinoma liver transplantation selection policies, Ann. \nSurg. 268 (4) (2018) 690\u2013699. \n[17] O. Ciccarelli, Q. Lai, P. Goffette, P. Finet, C. De Reyck, F. Roggen, et al., Liver \ntransplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic \npatients. Alpha-foetoprotein level and locoregional treatment as refined selection \ncriteria, Transpl. Int. 25 (8) (2012) 867\u2013875. \n[18] P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, A. Perrier, et al., \nRecommendations for liver transplantation for hepatocellular carcinoma: an \ninternational consensus conference report, Lancet Oncol. 13 (1) (2012) e11\u201322. \n[19] European Association for the Study of the Liver, Electronic address eee, European \nassociation for the study of the L. EASL clinical practice guidelines: management of \nhepatocellular carcinoma, J. Hepatol. 69 (1) (2018) 182\u2013236. \n[20] F.Y. Yao, Liver transplantation for hepatocellular carcinoma: beyond the Milan \ncriteria, Am. J. Transplant. 8 (10) (2008) 1982\u20131989. \n[21] M.L. Volk, S. Vijan, J.A. Marrero, A novel model measuring the harm of \ntransplanting hepatocellular carcinoma exceeding Milan criteria, Am. J. \nTransplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 8 (4) (2008) \n839\u2013846. \n[22] O. Detry, L. Govaerts, A. Deroover, M. Vandermeulen, N. Meurisse, S. Malenga, et \nal., Prognostic value of (18)F-FDG PET/CT in liver transplantation for \nhepatocarcinoma, World J. Gastroenterol. 21 (10) (2015) 3049\u20133054. \n[23] E. Melloul, M. Lesurtel, B.I. Carr, P.A. Clavien, Developments in liver \ntransplantation for hepatocellular carcinoma, Semin. Oncol. 39 (4) (2012) \n510\u2013521. \n[24] E.K. Geissler, A.A. Schnitzbauer, C. Zulke, P.E. Lamby, A. Proneth, C. Duvoux, et \nal., Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a \nrandomized, multicenter, open-label phase 3 trial, Transplantation 100 (1) (2016) \n116\u2013125. \n[25] J. Lerut, S. Iesari, M. Foguenne, Q. Lai, Hepatocellular cancer and recurrence after \nliver transplantation: what about the impact of immunosuppression? Transl. \nGastroenterol. Hepatol. 2 (2017) 80. \n[26] Q. Lai, A. Vitale, M. Rossi, U. Cillo, J. Lerut, European hepatocellular cancer liver \ntransplantation study G. Which is the true role of bridging therapies for HCC \npatients waiting for liver transplantation? Ann. Surg. (2017). \n[27] N. Mehta, J. Guy, C.T. Frenette, J.L. Dodge, R.W. Osorio, W.B. Minteer, et al., \nExcellent outcomes of liver transplantation following down-staging of \nhepatocellular carcinoma to within milan criteria: a multicenter study, Clin. \nGastroenterol. Hepatol.: Off Clin. Prac. J. Am. Gastroenterol. Assoc. 16 (6) (2018) \n955\u2013964. \n[28] W.C. Chapman, S. Garcia-Aroz, N. Vachharajani, K. Fowler, N. Saad, Y. Lin, et al., \nLiver transplantation for advanced hepatocellular carcinoma after downstaging \nwithout up-front stage restrictions, J. Am. Coll. Surg. (2017). \n[29] G. Sapisochin, N. Goldaracena, J.M. Laurence, M. Dib, A. Barbas, A. Ghanekar, et",
        "chunk_id": 11,
        "paper_title": "Surgical Oncology 33 (2020) 231\u2013238",
        "doi": "10_1016_j_suronc_2019_10_006",
        "year": 2019.0,
        "filename": "10_1016_j_suronc_2019_10_006.txt"
    },
    {
        "score": 2.7245168685913086,
        "text": "Asian Pacific Journal of Cancer Prevention, Vol 21 2911\nDOI:10.31557/APJCP.2020.21.10.2903\nResection Criteria for Intermediate Stage HCC\nretrospective, exploratory analysis. Lancet Oncol, 10, 35-43.\nQi X, Wang D, Su C, et al (2015). Hepatic resection versus \ntransarterial chemoembolization for the initial treatment of \nhepatocellular carcinoma: A systematic review and meta\ufffeanalysis. Oncotarget, 6, 18715-33.\nShimamura T, Akamatsu N, Fujiyoshi M, et al (2019). Expanded \nliving-donor liver transplantation criteria for patients with \nhepatocellular carcinoma based on the Japanese nationwide \nsurvey: the 5-5-500 rule - a retrospective study. Transpl Int, \n32, 356-68.\nTada T, Kumada T, Toyoda H, et al (2017). Role of hepatic \nresection in patients with intermediate-stage hepatocellular \ncarcinoma: A multicenter study from Japan. Cancer Sci, \n108, 1414-20.\nTakada Y, Ito T, Ueda M, et al (2007). Living donor liver \ntransplantation for patients with HCC exceeding the Milan \ncriteria: a proposal of expanded criteria. Dig Dis, 25, 299-\n302.\nThe Japan Society of Hepatology (2013). Clinical Practice \nGuidelines for Hepatocellular Carcinoma 2013. Kanehara \nCo, Ltd.\nTorre LA, Bray F, Siegel RL, et al (2015). Global cancer \nstatistics, 2012. CA Cancer J Clin, 65, 87-108.\nTorzilli G, Belghiti J, Kokudo N, et al (2013). A snapshot of the \neffective indications and results of surgery for hepatocellular \ncarcinoma in tertiary referral centers: is it adherent to the \nEASL/AASLD recommendations?: an observational study \nof the HCC East-West study group. Ann Surg, 257, 929-37.\nWada H, Eguchi H, Noda T, et al (2016). Selection criteria for \nhepatic resection in intermediate-stage (BCLC stage B) \nmultiple hepatocellular carcinoma. Surgery, 160, 1227-35.\nYamakado K, Kudo M (2014). Treatment strategies of \nintermediate-stage hepatocellular carcinomas in Japan \n(Barcelona Clinic Liver Cancer stage B). Oncology, 87, \n78-81.\nYin L, Li H, Li AJ, et al (2014). Partial hepatectomy vs. \ntranscatheter arterial chemoembolization for resectable \nmultiple hepatocellular carcinoma beyond Milan Criteria: \na RCT. J Hepatol, 61, 82-8.\nZhong JH, Ke Y, Gong WF, et al (2014). Hepatic resection \nassociated with good survival for selected patients with \nintermediate and advanced-stage hepatocellular carcinoma. \nAnn Surg, 260, 329-40.\nZhong JH, Xiang BD, Gong WF, et al (2013). Comparison \nof long-term survival of patients with BCLC stage B \nhepatocellular carcinoma after liver resection or transarterial \nchemoembolization. PLoS One, \n8, e68193.\nThis work is licensed under a Creative Commons Attribution\ufffeNon Commercial 4.0 International License.",
        "chunk_id": 11,
        "paper_title": "New Hepatic Resection Criteria for Intermediate-Stage",
        "doi": "10_31557_apjcp_2020_21_10_2903",
        "year": 2012.0,
        "filename": "10_31557_apjcp_2020_21_10_2903.txt"
    },
    {
        "score": 2.4273314476013184,
        "text": "hepatocellular carcinoma. Gastroenterology 2018;154(01):\n128\u2013139\n33 Sapisochin G, Goldaracena N, Laurence JM, et al. The extended\nToronto criteria for liver transplantation in patients with hepato\ufffecellular carcinoma: a prospective validation study. Hepatology\n2016;64(06):2077\u20132088\n34 Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor\nvolume and alpha-fetoprotein for selection of transplant candi\ufffedates with hepatocellular carcinoma: a prospective validation.\nHepatology 2015;62(01):158\u2013165\n35 Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as\nexpanded selection criteria for liver transplantation for hepato\ufffecellular carcinoma. Surgery 2013;154(05):1053\u20131060\n36 Bertsimas D, Kung J, Trichakis N, Wang Y, Hirose R, Vagefi PA.\nDevelopment and validation of an optimized prediction of mor\ufffetality for candidates awaiting liver transplantation. Am J Trans\ufffeplant 2019;19(04):1109\u20131118\n37 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver\ntransplantation for hepatocellular carcinoma: Where do we\nstand? World J Gastroenterol 2019;25(21):2591\u20132602\nSeminars in Liver Disease Vol. 40 No. 4/2020\n364 Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy Heimbach\nDownloaded by: NYU. Copyrighted material.",
        "chunk_id": 11,
        "paper_title": "Article published online: 2020-09-17",
        "doi": "10_1055_s-0040-1709492",
        "year": 2020.0,
        "filename": "10_1055_s-0040-1709492.txt"
    },
    {
        "score": 2.168445587158203,
        "text": "carcinoma. Surgery\u00a02013;154:1053-60. doi:10.1016/j.\nsurg.2013.04.056\u00a0\n71\u00a0 Mehta N, Guy J, Frenette CT, et al. Excellent outcomes of liver \ntransplantation following down-staging of hepatocellular carcinoma \nto within Milan Criteria: a multicenter study. Clin Gastroenterol \nHepatol\u00a02018;16:955-64. doi:10.1016/j.cgh.2017.11.037\u00a0\n72\u00a0 Organ Procurement and Transplantation Network. Policies. 2020.\nhttps://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.\n73\u00a0 Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. \nExcess mortality on the liver transplant waiting list: unintended \npolicy consequences and Model for End-Stage Liver Disease (MELD) \ninflation. Hepatology\u00a02015;61:285-91. doi:10.1002/hep.27283\u00a0\n74\u00a0 Tschuor C, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA, \nLiver Allocation Study Group. Allocation of liver grafts worldwide - Is \nthere a best system?J Hepatol\u00a02019;71:707-18. doi:10.1016/j.\njhep.2019.05.025\u00a0\n75\u00a0 Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with \nhepatocellular carcinoma awaiting liver transplantation: A systematic \nreview and meta-analysis. Hepatology\u00a02018;67:381-400. \ndoi:10.1002/hep.29485\u00a0\n76\u00a0 Fisher RA, Kulik LM, Freise CE, et al, A2ALL Study Group. \nHepatocellular carcinoma recurrence and death following living and \ndeceased donor liver transplantation. Am J Transplant\u00a02007;7:1601-\n8. doi:10.1111/j.1600-6143.2007.01802.x\u00a0\n77\u00a0 Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor \nversus deceased donor liver transplantation for early irresectable \nhepatocellular carcinoma. Br J Surg\u00a02007;94:78-86. doi:10.1002/\nbjs.5528\u00a0\n78\u00a0 Kulik LM, Fisher RA, Rodrigo DR, et al, A2ALL Study Group. \nOutcomes of living and deceased donor liver transplant recipients \nwith hepatocellular carcinoma: results of the A2ALL cohort. \nAm J Transplant\u00a02012;12:2997-3007. doi:10.1111/j.1600-\n6143.2012.04272.x\u00a0\n79\u00a0 Wong TCL, Ng KKC, Fung JYY, et al. Long-term survival outcome \nbetween living donor and deceased donor liver transplant for \nhepatocellular carcinoma: intention-to-treat and propensity \nscore matching analyses. Ann Surg Oncol\u00a02019;26:1454-62. \ndoi:10.1245/s10434-019-07206-0\u00a0\n80\u00a0 Goldaracena N, Gorgen A, Doyle A, et al. Live donor liver \ntransplantation for patients with hepatocellular carcinoma offers \nincreased survival vs. deceased donation. J Hepatol\u00a02019;70:666-\n73. doi:10.1016/j.jhep.2018.12.029\u00a0\n81\u00a0 Kwong A, Kim WR, Lake JR, et al. OPTN/SRTR 2018 annual data \nreport: liver. Am J Transplant\u00a02020;20(Suppl s1):193-299. \ndoi:10.1111/ajt.15674\u00a0\n82\u00a0 Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for \nhepatocellular carcinoma: comparison of various ablation techniques \nand surgery. Can J Gastroenterol Hepatol\u00a02018;2018:4756147. \ndoi:10.1155/2018/4756147\u00a0\nProtected by copyright, including for uses related to text and data mining, AI training, and similar technologies. \n. Technical Services Serials\nat New York University, Serials Bobst Library on 3 November 2025 https://www.bmj.com/ Downloaded from 26 October 2020. 10.1136/bmj.m3544 on BMJ: first published as",
        "chunk_id": 26,
        "paper_title": "New advances in the diagnosis and management of",
        "doi": "10_1136_bmj_m3544",
        "year": 2020.0,
        "filename": "10_1136_bmj_m3544.txt"
    },
    {
        "score": 2.1289100646972656,
        "text": "patients initially outside the Milan selection criteria. Am J Transplant 2008;\n8:2547\u20132557. doi: 10.1111/j.1600-6143.2008.02409.x.\n[31] Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoemboliza\ufffetion: modalities, indication, and patient selection. J Hepatol 2015;62:\n1187\u20131195. doi: 10.1016/j.jhep.2015.02.010.\n[32] Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or\nbenefit? Transl Gastroenterol Hepatol 2017;2:106. doi: 10.21037/tgh.\n2017.11.18.\n[33] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepato\ufffecellular carcinoma. Semin Liver Dis 2010;30:52\u201360. doi: 10.1055/s-0030-\n1247132.\n[34] Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs\nAK, et al. EASL and mRECIST responses are independent prognostic factors\nfor survival in hepatocellular cancer patients treated with transarterial embo\ufffelization. J Hepatol 2011;55:1309\u20131316. doi: 10.1016/j.jhep.2011.03.007.\n[35] Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. Hep\ufffeatocellular carcinoma: CT for tumor response after transarterial chemoem\ufffebolization in patients exceeding Milan criteria\u2013selection parameter for liver\ntransplantation. Radiology 2010;255:289\u2013300. doi: 10.1148/radiol.\n09090927.\n[36] Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, et al. Recurrence\nof hepatocellular carcinoma: importance of mRECIST response to chemo\ufffeembolization and tumor size. Am J Transplant 2014;14:1383\u20131390. doi:\n10.1111/ajt.12684.\n[37] Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al.\nStanding the test of time: outcomes of a decade of prioritizing patients with\nhepatocellular carcinoma, results of the UNOS natural geographic experi\ufffement. Hepatology 2014;60:1957\u20131962. doi: 10.1002/hep.27272.\n[38] Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and\nwait versus rapid transplantation. Liver Transpl 2010;16:925\u2013929. doi: 10.\n1002/lt.22103.\n[39] National Liver Review Board (NLRB) Frequently asked questions for candi\ufffedates and caregivers. Available from: https://optn.transplant.hrsa.gov/me\ufffedia/2797/201901_nlrb_faq_patient.pdf.\n[40] Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recom\ufffemendations for liver transplantation for hepatocellular carcinoma: an inter\ufffenational consensus conference report. Lancet Oncol 2012;13:e11\u2013e22. doi:\n10.1016/S1470-2045(11)70175-9.\n[41] Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al.\nValidation of a risk estimation of tumor recurrence after transplant\n(RETREAT) score for hepatocellular carcinoma recurrence after liver trans\ufffeplant. JAMA Oncol 2017;3:493\u2013500. doi: 10.1001/jamaoncol.2016.5116.\nJournal of Clinical and Translational Hepatology 2020 vol. 8 | 69\u201375 75\nLingiah V.A. et al: Liver transplantation beyond Milan criteria",
        "chunk_id": 14,
        "paper_title": "Liver Transplantation Beyond Milan Criteria",
        "doi": "10_14218_JCTH_2019_00050",
        "year": 2020.0,
        "filename": "10_14218_JCTH_2019_00050.txt"
    },
    {
        "score": 2.1283204555511475,
        "text": "STATE OF THE ART REVIEW\nthe\u2009bmj | BMJ 2020;371:m3544 | doi: 10.1136/bmj.m3544 7\ntransplantation.73 In the United Kingdom, a benefit \nmodel was adopted in 2018, which prioritises urgent \ncases and those with the highest anticipated benefit \nfrom liver transplantation by combining multiple \ndonor and recipient parameters, including the \nrecipient\u2019s diagnosis of hepatocellular carcinoma.74\nThe Euro-transplant and Italian systems both use \nMELD based approach with additional exception \npoints awarded for hepatocellular carcinoma, while \nthe French system incorporates \u03b1 fetoprotein and \nrequires hepatocellular carcinoma treatment.74\nPatients waiting for liver transplantation are at risk of \ndisease progression, and many types of neoadjuvant \nliver directed treatments such as TACE, TARE, \nradiofrequency ablation, and stereotactic body \nradiation therapy (SBRT) have been used to reduce \nthe risk of patients dropping out of the waiting list. \nHowever, problems such as whether the treatment \nwas used to downstage or prevent progression, \nthe highly variable waiting time, and the lack of a \ncomparative group confound interpretation. Based \non the available evidence, one treatment cannot be \nrecommended over another.75 The main benefit of \nTACE is the ability to treat multiple lesions and lack \nof needle track seeding, while TARE might require \nfewer treatments and no hospital admission. The \nbenefits of radiotherapy are currently being assessed \nin ongoing studies.\nLiving donor liver transplantation is also an \noption for patients with hepatocellular carcinoma, \nwhich has continued to flourish around the world, \nmost notably in Asia. But growth of the procedure \nhas been slow in the US for both patients with \nand without hepatocellular carcinoma, in part \ndue to donor safety concerns.76 77 Initial concern \nof an increased risk of hepatocellular carcinoma \nrecurrence after living donor liver transplantation \nhas since been determined to be primarily related to \npatient selection, and improved survival after living \ndonor liver transplantation compared with deceased \ndonor liver transplantation has been reported when \nanalyzed on an intention-to-treat basis, due to a \nreduced risk of patients dropping out of the waiting \nlist.78-80 Owing to the ongoing critical organ shortage \nand recent allocation changes, living donor liver \ntransplantation is currently increasing in the US \nfor both patients with and without hepatocellular \ncarcinoma.81\nAblation\nAblation is highly efficacious for tumors up to 3 cm \nin diameter, but its efficacy decreases once tumors \nare larger than 3 cm. Many treatment modalities \nare available for the local ablation of hepatocellular \ncarcinoma with generally similar outcomes.82-86\nRadiofrequency ablation and microwave ablation \nare the most commonly used ablation treatments. \nA recent, multicenter, single blinded, phase II \nrandomized controlled trial enrolled 76 patients \nfor radiofrequency ablation and 76 patients for \nmicrowave ablation; patients each had a maximum \nof three hepatocellular carcinoma lesions of up to 4 \ncm each. The study showed an association between \nmicrowave ablation and higher rates of local tumor \ncontrol (relative ratio 1.6, 95% confidence interval \n0.7 to 3.9).84 However, another randomized trial \nof 93 patients with hepatocellular carcinoma \nreceiving microwave ablation or radiofrequency \nablation showed no difference in treatment related \nmorbidity, overall survival, or disease free survival, \nTable\u00a01 | Ongoing immunotherapy based phase III clinical trials for hepatocellular carcinoma\nTreatment type and target population Treatment\nEnrollment goal \n(No of participants) \nPrimary \nendpoint Trial registration Status\nFirst line systemic treatment\nNo previous systemic treatment, BCLC B or C \nstage, not eligible for locoregional treatment \n(Child-Pugh class A, ECOG performance \nstage 0-1)\nLenvatinib+pembrolizumab v\nlenvatinib+placebo\n750 OS, PFS NCT03713593 Recruiting; anticipated",
        "chunk_id": 11,
        "paper_title": "New advances in the diagnosis and management of",
        "doi": "10_1136_bmj_m3544",
        "year": 2020.0,
        "filename": "10_1136_bmj_m3544.txt"
    }
]